1-Phenylcyclohexan-1-amine hydrochloride (PCA HCl) alters mesolimbic dopamine system accompanied by neuroplastic changes : A neuropsychopharmacological evaluation in rodents
Copyright © 2021 Elsevier Ltd. All rights reserved..
The recreational use of N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) and ketamine have grown rapidly due to their psychotomimetic properties. These compounds induce both non-fatal and fatal adverse effects and despite the enhanced regulation, they are continuously synthesized and are being sold in the illegal drug market, including 1-phenylcyclohexan-1-amine hydrochloride (PCA). Therefore, we evaluated its abuse potential through the conditioned-place preference (CPP), self-administration, and locomotor sensitization paradigms. Pretreatment with SCH 2 3390 and haloperidol was also performed during a CPP test. We used ELISA to measure dopamine (DA) levels and western blotting to determine effects on the DA-related proteins as well as on phosphorylated CREB, deltaFosB, and brain-derived neurotrophic factor (BDNF) in the ventral tegmental area (VTA) and nucleus accumbens (NAc). Finally, we examined the effects on brain wave activity using electroencephalography (EEG). PCA induced CPP in mice and was self-administered by rats, suggesting that PCA has rewarding and reinforcing properties. PCA increased locomotor of mice on the first treatment and challenge days. SCH 23390 and haloperidol blocked the CPP. PCA altered the DA, tyrosine hydroxylase, dopamine D1 and D2 receptors as well as p-CREB and deltaFosB. Also, PCA altered the delta and gamma waves in the brain, which were then normalized by SCH 2 3390 and haloperidol. The present findings indicate that PCA may induce abuse potential through the dopaminergic system and probably accompanied with alterations in brain wave activity which is similar to that of other psychotomimetic NMDA antagonists. We advocate thorough monitoring of PCP analogs as they pose potential harm to public health.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:144 |
---|---|
Enthalten in: |
Neurochemistry international - 144(2021) vom: 28. März, Seite 104962 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Abiero, Arvie [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 12.11.2021 Date Revised 12.11.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.neuint.2021.104962 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM320232956 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM320232956 | ||
003 | DE-627 | ||
005 | 20231225173135.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.neuint.2021.104962 |2 doi | |
028 | 5 | 2 | |a pubmed24n1067.xml |
035 | |a (DE-627)NLM320232956 | ||
035 | |a (NLM)33460722 | ||
035 | |a (PII)S0197-0186(21)00008-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Abiero, Arvie |e verfasserin |4 aut | |
245 | 1 | 0 | |a 1-Phenylcyclohexan-1-amine hydrochloride (PCA HCl) alters mesolimbic dopamine system accompanied by neuroplastic changes |b A neuropsychopharmacological evaluation in rodents |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 12.11.2021 | ||
500 | |a Date Revised 12.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
520 | |a The recreational use of N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) and ketamine have grown rapidly due to their psychotomimetic properties. These compounds induce both non-fatal and fatal adverse effects and despite the enhanced regulation, they are continuously synthesized and are being sold in the illegal drug market, including 1-phenylcyclohexan-1-amine hydrochloride (PCA). Therefore, we evaluated its abuse potential through the conditioned-place preference (CPP), self-administration, and locomotor sensitization paradigms. Pretreatment with SCH 2 3390 and haloperidol was also performed during a CPP test. We used ELISA to measure dopamine (DA) levels and western blotting to determine effects on the DA-related proteins as well as on phosphorylated CREB, deltaFosB, and brain-derived neurotrophic factor (BDNF) in the ventral tegmental area (VTA) and nucleus accumbens (NAc). Finally, we examined the effects on brain wave activity using electroencephalography (EEG). PCA induced CPP in mice and was self-administered by rats, suggesting that PCA has rewarding and reinforcing properties. PCA increased locomotor of mice on the first treatment and challenge days. SCH 23390 and haloperidol blocked the CPP. PCA altered the DA, tyrosine hydroxylase, dopamine D1 and D2 receptors as well as p-CREB and deltaFosB. Also, PCA altered the delta and gamma waves in the brain, which were then normalized by SCH 2 3390 and haloperidol. The present findings indicate that PCA may induce abuse potential through the dopaminergic system and probably accompanied with alterations in brain wave activity which is similar to that of other psychotomimetic NMDA antagonists. We advocate thorough monitoring of PCP analogs as they pose potential harm to public health | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a 1-Phenylcyclohexan-1-amine hydrochloride (PCA HCl) | |
650 | 4 | |a Abuse potential | |
650 | 4 | |a Electroencephalography | |
650 | 4 | |a Mesolimbic dopamine system | |
650 | 7 | |a Cyclohexylamines |2 NLM | |
650 | 7 | |a 1-phenylcyclohexylamine |2 NLM | |
650 | 7 | |a HBO2D49I2S |2 NLM | |
650 | 7 | |a Dopamine |2 NLM | |
650 | 7 | |a VTD58H1Z2X |2 NLM | |
700 | 1 | |a Perez Custodio, Raly James |e verfasserin |4 aut | |
700 | 1 | |a Botanas, Chrislean Jun |e verfasserin |4 aut | |
700 | 1 | |a Ortiz, Darlene Mae |e verfasserin |4 aut | |
700 | 1 | |a Sayson, Leandro Val |e verfasserin |4 aut | |
700 | 1 | |a Kim, Mikyung |e verfasserin |4 aut | |
700 | 1 | |a Lee, Hyun Jun |e verfasserin |4 aut | |
700 | 1 | |a Yoon, Seolmin |e verfasserin |4 aut | |
700 | 1 | |a Lee, Yong Sup |e verfasserin |4 aut | |
700 | 1 | |a Cheong, Jae Hoon |e verfasserin |4 aut | |
700 | 1 | |a Kim, Hee Jin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Neurochemistry international |d 1980 |g 144(2021) vom: 28. März, Seite 104962 |w (DE-627)NLM012652016 |x 1872-9754 |7 nnns |
773 | 1 | 8 | |g volume:144 |g year:2021 |g day:28 |g month:03 |g pages:104962 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neuint.2021.104962 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 144 |j 2021 |b 28 |c 03 |h 104962 |